Current / Active Enrolling Trials

Vascular Associates is a designated center in Baton Rouge, Louisiana, for the National Institutes of Health (NIH)-sponsored Carotid Revascularization: Endarterectomy vs. Stenting Trial (CREST) Trial (www.cresttrial.org).  The trial studies the efficacy and safety of carotid stenting versus conventional surgery in low risk individuals. This is the largest currently enrolling randomized trial in North America comparing the use of these two modalities in preventing stroke, myocardial infarction, and death in the population at risk.

Abdominal Aortic Aneurysm (AAA) Trial sponsored by Medtronix and the Cleveland Clinic Foundation, PIVOTAL- Positive Impact of EndoVascular Options for Treating Aneurysms Early. If you have an AAA, schedule an appointment with one of our physicians to see if you’re an eligible candidate. 

Vascular Associates is one of only 40 centers chosen nationwide to participate in a post-marketing trial of the SilverHawk Device, a new device that is FDA-Approved to cut occluding plaque (atherosclerotic lesions) directly off the wall of a diseased artery.  Further, we have enrolled the first 2 patients in the nation in this exciting study to determine the safety, effectiveness, and cost over time of the Silverhawk device compared with bypass surgery. 

Vascular Associates is also on the cutting edge in the treatment of deep vein thrombosis (DVT, or blood clot).  New techniques and technology are in practice every day.  As a research site for the “TRELLIS” Device study called STRIDE, the surgeons are discovering promising new therapeutic options for persons in the treatment and removal of new-onset blood clots (DVT).  Again, our site has led the way and is ranked #1 nationwide in enrollment into this study.

Vascular Associates is participating in a trial sponsored by the National Institutes of Health that is researching the effects of the drug Aggrenox on patency of the graft (dialysis access) over time in hemodialysis patients.

Vascular Associates remains one of the only centers in the United States to offer laparoscopic aortic reconstruction. Certified, we have performed these procedures in selected patients with excellent results that have been presented at national and international scientific meetings. Our results have also been accepted for publication in the Journal of Vascular Surgery, the leading peer-reviewed publication in the field of vascular and endovascular surgery.

Vascular Associates has developed, supports and participates in an area-wide, quality outcomes registry for vascular patients (Surgisys - www.Surgisys.com) to assure that patient care is optimized. This provides consistent quality assurance and improvement by monitoring the complications and outcomes related to the patient’s vascular procedure. All data is entered in a prospective, ongoing database that links the entire enrolled medical community.

Selected Previous Clinical Trials

Glaxo Smith Kline (GSK ITI 101711) trial for Deep Vein Thrombosis prevention in patients undergoing Total Knee Replacement.

Ranked #1 in the US, Zymogenetics 499E01, a clinical trial that studied the effects of a hemostatic agent (drug that helps stop bleeding) that is used in surgery on the access in dialysis patients.

Ranked #1 in the US and 3rd in the world, Vascular Associates has been a leader in the clinical trial SOV302 (GE HealthCare) which assesses the efficacy and safety of a contrast agent used for Magnetic Resonance Angiography (MRA) of the arteries and compares its image quality to angiography.

Ranked in the top 3 sites for the Expedial Dialysis Access trial sponsored by LeMaitre Vascular.

Ranked #1 in the nation for enrollment, Vascular Associates has been a leading participant for the PREVENT V Multicenter clinical trial, a study testing the effects of treating the venous anastomosis during dialysis access surgery with a drug that can reduce narrowing and graft failure.

Ranked #1 in the nation for enrollment in the C.O.M.P.A.R.E. study which regards the post-market evaluation of a vascular clip (U-clip) device that has been shown to improve the maturity rate of AV Fistulas and durability of certain bypass procedures.

Ranked 6th in the nation for enrollment, Vascular Associates has been a leading participant for the PREVENT III clinical trial; a study testing the effects of treating vein grafts prior to bypass with a drug that reduces narrowing and graft failure.

Vascular Associates participated in the clinical trial DXV303 sponsored by Amersham Health. This study tested the efficacy and safety of a new contrast agent used for angiography. In addition, the study compared the data and outcomes between CT angiography versus conventional angiography.

The Flow Medica FEN 002 trial studied the direct intra-renal (kidney) infusion of Fenoldopam, medicine given to patients who are high risk for radiocontrast nephropathy (kidney failure) undergoing angiography.

We are dedicated to providing the best, most up-to-date care for our patients and thus will remain intimately involved in clinical research.